Deutsche Bank Downgrades Apogee Therapeutics to Hold
Deutsche Bank set a $135 price target for Apogee Therapeutics, downgrading it to a hold rating, a 1.75% upside from the current price.
Key Points
- Deutsche Bank downgraded Apogee Therapeutics to a hold rating with a price target of $135 on June 23, 2026.
- Deutsche Bank's $135 price target implies 1.75% upside from Apogee Therapeutics, Inc.'s ($APGE) current $132.68 share price.
- Shares of NasdaqGM:APGE traded near $132.55 on Tuesday, with a market cap of approximately $9.99 billion.
- T. Rowe Price Investment Management increased its holdings by 7,568,528 shares, now holding over 10.3 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Deutsche Bank has downgraded Apogee Therapeutics, Inc. (NasdaqGM: APGE) to a hold rating, setting a price target of $135. This rating change was announced on June 23, 2026, by analyst David Hoang.
Deutsche Bank vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Apogee Therapeutics
T. Rowe Price Investment Management significantly increased its stake in Apogee Therapeutics, adding 7,568,528 shares to hold a total of 10,300,984 shares valued at about $867 million, marking a 277% increase. Meanwhile, FMR LLC also grew its position by 1,037,253 shares, bringing its total to 9,262,291 shares worth approximately $780 million, a 12.6% increase. On the other hand, Wellington Management Group reduced its holdings by 370,882 shares, now holding 4,375,703 shares valued at around $368 million, reflecting a 7.8% decrease. BlackRock, Inc. added 301,657 shares, increasing its stake by 8% to 4,085,651 shares valued at roughly $344 million.
Apogee Therapeutics, Inc. Stock Down 1.7%
Shares of Apogee Therapeutics, Inc. traded near $132.55 on Tuesday. The company has a market cap of about $9.99 billion. It is not currently profitable, with a forward P/E ratio calculated at -25.52. The stock has a 52-week low of $34.34 and a high of $133.00. Its 50-day moving average is $84.76, and the 200-day moving average is $69.38. The company maintains a strong liquidity position with a current ratio of 32.59 and a quick ratio of 32.39. Its debt-to-equity ratio stands at 0.64.
$APGE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 23, 2026, Deutsche Bank downgraded Apogee Therapeutics to a hold rating, setting a price target of $135. Citigroup also downgraded the stock to hold with the same target, while UBS followed suit with a similar downgrade and target. RBC Capital maintained its hold rating with a target of $135, and Canaccord Genuity also downgraded its rating to hold with a $135.11 target. The consensus rating for Apogee Therapeutics is a strong buy, with a mean price target of $119.50 based on 16 analyst opinions.
About Apogee Therapeutics
Apogee Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing novel biologics for treating various inflammatory and immunological conditions, including atopic dermatitis, asthma, and eosinophilic esophagitis. The company is working on several clinical-stage therapies, with Zumilokibart (APG777) in phase 2 trials for atopic dermatitis. Apogee was founded in 2022 and is led by CEO Dr. Michael Thomas Henderson.
Bottom Line
Investors are keeping a close eye on Apogee Therapeutics following Deutsche Bank's downgrade to a hold rating and the new price target of $135. While institutional investors like T. Rowe Price have significantly increased their holdings, the stock remains volatile. This analyst activity provides insights into market sentiment, although 13F filings are inherently backward-looking and may not reflect current positions.
Get Apogee Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $APGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.